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ABSTRACT
With the rapid emergence of antibiotic resistant bacteria affecting people around the
world, research into new therapies using bacteriophages (phages) is increasing in the United
States. Phages are viruses that can only infect bacteria and are able to co-evolve alongside the
bacteria they infect. A researchers’ ability to pinpoint which phage to use in the therapy is
important to combat an infection effectively. To do so, the genes that control the interaction
between phages and the bacteria they infect, such as receptor binding proteins on the surface
of a bacterial cell, need to be identified. Transposon mutagenesis was used in our study to find
the receptor binding protein of Bacillus thuringiensis kurstaki (Btk). Btk was chosen as the
bacterial host because it is a naturally occurring soil bacteria that is commonly used as an
insecticide in agriculture, but is nonpathogenic to humans. The bacterium is also a close relative
to Bacillus anthracis, the causative agent of anthrax, and may share some phages. Using the EZTn5TM <R6Kyori/KAN-2> Tnp transposon kit, 134 individual mutant colonies were isolated on
kanamycin plates. Virulent bacteriophage Riley, a well-characterized phage infecting BtK, was
used to find phage-resistant bacteria in the mutant population. Three mutants, 1041, 1043, and
1221, were found to be resistant to bacteriophage Riley and will be further studied to
determine the interrupted gene. (Ventola, 2015)
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INTRODUCTION
On September 3, 1928, the major discovery of penicillin was made by Alexander Fleming
that would soon be deemed the miracle drug (Aminov, 2010). For decades after that discovery,
the western world has depended solely on antibiotics to treat bacterial infections. What many
did not realize was that every time a person was prescribed antibiotics, it increased the risk of
bacteria becoming resistant and, consequently, deadlier to the human population. Due to the
Cold War, many of the advances in antibiotics did not reach past the iron curtain into Eastern
Europe. Consequently, research into bacteriophage (phage) therapy increased, instead of being
pushed to the side like it was in the West (Nobrega, Costa, Kluskens, & Azeredo, 2015). With
the increase of the number of antibiotic resistant bacterial strains, phages are once again being
looked at as a treatment for bacterial diseases.
Unlike antibiotics, that have the tendency to kill more than just bacteria causing the
infection, bacteriophages have a high specificity to the bacteria they infect (Nobrega et al.,
2015). Their high specificity is also a limitation in phage therapy because they can only infect
one type of bacteria while an infection may include multiple types of pathogenic bacteria. To
combat this problem many scientists are creating phage cocktails that have multiple different
types of phages that can infect and destroy different types of bacteria (Chan, Abedon, & LocCarrillo, 2013). Another advantage to bacteriophages is that they only replicate at the site of
infection. Phages are self-limiting and self-dosing, preventing them from persisting when their
specific bacterial pathogen becomes absent (Nobrega et al., 2015). From a developmental point
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of view, phages have the advantage of rapid isolation, versatility of formulation and application,
and lower developmental costs than antibiotics (Nobrega et al., 2015).
Phage therapy has the advantage of being able affect multi-drug resistant bacteria and
biofilms because phages have specific receptor binding sites that allow them to infect a
bacterium even if it is resistant to antibiotics. Phages have a general lower tendency to induce
resistance and cross-resistance to antibiotics (Nobrega et al., 2015). Phage-resistance can,
however, occur in bacterial cells if the bacterium uses the Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR) system that is able to cause the degradation of the inserted
phage DNA or RNA, or phage absorption is blocked due to the mutation or loss of the bacterial
receptor on the surface of the bacterial cell (Nobrega et al., 2015). To combat bacteria’s natural
way of immunizing themselves against phages, a proposed solution is to genetically engineer
the phages using the CRISPR system.
Before genetic engineering can be done, research on the genes that control phage and
interaction with the bacterial cell must be completed. An important protein for the attachment
of the bacteriophage to the bacteria’s cell wall is the Receptor Binding Protein (RBP) located on
the surface of the bacterial wall. The first step in the infection by a bacteriophage is the
adsorption of the phage to the host cell (Bielmann et al., 2015). RBP is recognized by phage
receptor and allows the phage to attach to the cell wall (Bielmann et al., 2015). The RBP
recognition and binding is extremely specific, and high affinity is required for rapid and efficient
virus attachment (Bielmann et al., 2015). According to Bielmann, the precise mechanism by
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which a phage particle recognizes, adsorbs to, and infects a bacterial cell is only poorly
understood, especially for phages infecting Gram-positive pathogens (Bielmann et al., 2015).
Though they are difficult to identify using
standard procedures, RBPs can be used as
diagnostic tools and therapeutics in the
biotech industry (Sacher, 2016). For these
therapeutics to be successful, the structures
of the host cell that will allow phage
Figure 1: Rescue Cloning of Interrupted Gene and
Transposon (TNP & KIT, 2017)

interaction must be analyzed. (Sacher, 2016).

Transposon Mutagenesis
To analyze RBPs, the technique of transposon mutagenesis can be used to find and
isolate the gene. Transposons are genetic elements that go through the recombination process
of transposition in which they can relocate from one genomic location to another (Reznikoff,
1993)(Hayes, 2003). Transposons are found in both prokaryotic and eukaryotic cells and can be
used as in vivo or in vitro interrupters (Hayes, 2003). Tn5 is a type of transposon that moves
from its resident position to another location by a cut-and-paste mechanism (Hayes, 2003). The
Tn5 transposon from the EZ-Tn5 <R6kγori/KAN-2> transposon kit contains the kanamycin
resistant gene KANR that allows antibiotics resistance to be used as a selection phenotype (Tnp
& Kit, 2017). The R6kγori gene allows the transposon to self-ligate into a plasmid after the DNA
from the mutant is extracted and sheared so that it can be transformed into E. coli to be
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rescued, as seen in Figure 1 (Tnp & Kit, 2017). The
transposon map (Figure 2) indicates that the KANR
gene and the R6kγori gene fall in the middle of the
transposon’s genomic sequence. The additional
genes allow the researcher to ensure that the
transposon has interrupted a gene. The Tn5
transposon can be inserted into the bacteria’s
chromosome using electroporation (Figure 3).
Electroporation is the process of using electrical

Figure 2: Ez-Tn5 <R6kγori/Kan-2>
Transposon (Tnp & Kit, 2017)

pulses to create pores that allow genetic material to permeate the bacterial membrane of
electrocompetent cells (“Electrocompetent
Cells,” n.d.). The EZ-Tn5 transposase is then
activated by the Mg2+ that is located in the cell’s
environment and randomly inserts into the
host’s DNA (Tnp & Kit, 2017). The cells that took
Figure 3: Transposon mutagenesis using
electroporation (Tnp & Kit, 2017)

up the transposon can be grown on kanamycin
(KAN) plates so that the genes that were

interrupted can be found and analyzed.
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Bacillus thurgiensis kurstaki and Bacteriophage Riley
Bacillus thurgiensis kurstaki (BtK) (Figure 4) is a Grampositive bacterium that is found abundantly in soil. It is used
in industry as a natural insecticide to certain types of
caterpillars (Olkowski, Daar, & Olkowski, 2009). It is a nonpathogenic bacterium that can be safely handled in a
Biosafety Level 1 lab. Since it is in the lowest Biosafety Risk

Figure 4: Bacillus thurgiensis
Kurstaki (Sahay, 2013)

Group, BtK is a safe candidate to create mutants with transposon mutagenesis.
Riley (Figure 5) is a myoviris bacteriophage that was
discovered and characterized by students at Mary Washington
University. It is a virulent phage that only goes through the lytic
cycle. This attribute allows Riley to be a candidate for phage
therapy because it would infect and destroy the bacteria
without going into the lysogenic cycle, which could leave some
Figure 5: Bacteriophage Riley
bacteria alive.
(Sauder Et Al., 2016)
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OBJECTIVE
The main purpose of this project was to further our knowledge about the genes that
allow the interactions between bacteriophages and the bacteria they infect. The overall goal
was to find the receptor binding protein using transposon mutagenesis to construct mutants
that are resistant to bacteriophage Riley and then to sequence the interrupted gene.
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METHODS:
Multiplicity of Infection:
The Multiplicity of infection (MOI) for Bacillus thurgiensis kurstaki (BtK) was calculated
to find the amount of BtK needed to infect LB plates. To find the MOI, 3.0 mL of enriched BtK
and SM buffer (100mM NaCl, 8 mM MgSO4·7H2O, 50 mM Tris-Cl (1 M, pH 7.5), 0.01% (w/v)
Gelatin (2%, w/v), 1 liter H2O) was placed in a tube labeled 100. A 10-fold dilution out to 10-4
was then made with SM buffer and the bacterial culture. A Bausch and Lomb Spectronic 20
spectrometer was used to measure the optical density (OD) at 600nm for each dilution. Then
100 µL of each dilution was spread on separate LB plates. The plates were then placed into an
incubator at 37°C for 24 hours. The titer was then calculated for the 10-4 dilution using the
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠

1000 𝜇𝐿
) × 𝑡ℎ𝑒
1𝑚𝐿

following formula: (𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑙𝑎𝑐𝑒𝑑 𝑜𝑛 𝑝𝑙𝑎𝑡𝑒) × (

𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟

Testing Bacteriophages:
The bacteria culture was diluted to 10-2 and 100 µL of the dilutions 100 to 10-2 were
pipetted into 5 mL top agar and poured onto separate plates. Five microliters of high titer lysate
of bacteriophages Riley, Troll, Megaron, and CAM003 were placed onto designated spaces on
each plate. The plates were then placed into the incubator at 37°C for 24 hours. The test was
used to see which phage would infect the bacteria with the clearest spot with the given
concentration of phages.
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Transposon Mutagenesis:
The purpose of this protocol was to prepare the cells for electroporation and then deliver
the transposon. The BtK cells were prepared for electroporation by inoculating a colony of BtK in
10 mL of LB in a 125-mL flask and then incubating the culture overnight at 37°C in a shaking
incubator at 250 RPM. Five hundred milliliters of BHI were incubated overnight as well. After 24
hours, 2 mL of the BtK culture were pipetted into the heated BHI flask and incubated at 28°C in
the shaking incubator at 300 RPM. The cultures were monitored until the OD600 reached 0.3 OD,
which is approximately 1.0 x 107cells/mL as calculated by colony forming units. At this point, the
culture was chilled on ice for 10 minutes. The cells were then transferred into two chilled 250 mL
centrifuge bottles and centrifuged at 4°C for 10 minutes at 10,000 x g to form a pellet at the
bottom of the tube. After discarding the supernatant, the pellet was resuspended with 50 mL of
sterile ice-cold EP buffer (0.5 mM K2HPO4–KH2PO4, 0.5 mM MgCl2, 272 mM Sucrose). The cells
were pelleted as before with the chilled centrifuge. After pelleting the cells, the supernatant was
discarded and the pellet was resuspended in 15 mL of sterile, ice cold EP buffer. The cells were
then transferred into 40 mL Oak Ridge tubes and centrifuged for 10 minutes at 10,000 x g. The
supernatant was discarded and the pellet was resuspended in 0.5 mL of ice cold EP buffer and
kept on ice.
To electroporate the cells, 1 µL of transposon DNA was pipetted into 100 µL of the
electrocompetent BtK cells. The solution was mixed and incubated on ice for 5 to 10 minutes.
After incubating the cells, 100 µL of the transposon-cell suspension was transferred to a chilled
0.2 cm cuvette on ice. A microcentrifuge tube for each sample was prepared with 2.0 mL of LB
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broth and incubated at room temperature. The cuvette was tapped to get the solution to the
bottom of the cuvette. The Bio-RAD Gene Pulser X cell (Bio-Rad, [Hercules, CA]) was used with a
Bacillus-specific protocol from the instrument manufacturer to electroporate the cells. The
cuvette was then placed in the ShockPod and the chamber lid was closed. The pulse parameter
was checked to see if the time constant was approximately 8.6 milliseconds and the voltage
was approximately 1.0 KV. After pressing the pulse button, the cuvette was removed from the
chamber and 200 µL of the room temperature LB broth was immediately added to the cuvette.
The cells from the cuvette were then transferred to the tube containing the LB broth. The
process was then repeated for the negative control (no DNA added to the bacterial cells). The
two tubes were then incubated for 1.5 hours at 37°C in the shaking incubator at 250 rpm. The
cell cultures were then plated on kanamycin-LB (50 ug/mL) plates at 100 µL per plateand
incubated at 37°C for 48 hours. The colonies that grew were cultured eight at a time on KAN
plates.
Bacteriophage Resistance testing:
The mutants were named by taking the number of their plate and their position on the
plate. An example of this would be mutant 1043 where the mutant was on plate 10 as the 43rd
mutant cultured. The next step was to use full plates infections (FPI) to find mutants that are
resistant to bacteriophage Riley. The FPI started by labeling five microcentrifuge tubes 100 to
10-4. For the 100 microtube, 100 µL of LB was pipetted into the tube. Ninety microliters of LB
was pipetted into the rest of the labeled tubes. Eight mutants were then picked and put into
one 100 tubes to make a pool. Ten microliters from the 100 tube was pipetted into the 10-1
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tube. This was then repeated for the rest of the dilution series. One hundred microliters of
phage HTL was pipetted into each tube. After the tubes were mixed by vortexing, 190 µL of
each dilution was pipetted onto separate KAN plates and incubated at 37°C for 24 hours. This
technique was then repeated for the rest of the mutants, but only using dilutions 10-3 and 10-4
since their lawns had the most coverage on the plate.
The colonies were then tested against phage Riley using spot tests to identify mutants
that were resistant to the bacteriophage. To do this, the mutant colonies were individually
picked and then placed in 5 µL of LB broth and incubated in the shaker at 37°C for 48 hours. The
cultures were then plated on KAN plates by pipetting 50 µL of the culture onto the plate and
spread by using an L-shaped spreader. Five microliters of the high titer lysate (HTL) of Riley was
then spotted on the plate and left to dry. The plates were placed in the incubator at 37°C for 48
hours. The spot test protocol was repeated twice more using 100 μL of the culture on the
plates until there were 8 mutants that showed consistent and stable phage resistance. After
repeated testing, 3 mutants - 1041, 1043, and 1221 - were retained due to highly consistent
resistance results.
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RESULTS
In this study, a suitable phage was chosen and optimized for infectivity against BtK. Lack
of infection by this phage was used to screen a transposon mutant library of BtK. The process
yielded three resistant mutants, which are currently being analyzed.
Multiplicity of Infection and testing bacteriophages:
BtK was diluted to 10-4 and was determined that the
CAM003

10-4 dilution yielded a confluent lawn of approximately
7.6 x 106 cfu/mL. Bacteriophage Riley was chosen as
Megatron

Troll
Riley

Figure 6: Dilution 100 with phage spots

the phage to test against the mutants (Figure 6). The
MOI chosen was 100 since it had the most consistent
lawn coverage, as seen in Figure 6.

Transposon Mutagenesis:
The time constant for the control BtK for
electroporation was 9.6 msec and the voltage was 989
V. The time constant for the bacteria-plasmid solution
was 8.1 msec and the voltage was 986 V. A total of
134 mutants (Figure 7) were produced in two
experiments. A few cells were found on the control,

Figure 7: 7 out of 134 Btk mutant
cultures created by transposon

but were not consistent enough throughout the plates
to warrant a new test.
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Bacteriophage Resistance
Mutants from plates 10, 11, 12, and 13 were able to grow on the plates after being
tested against bacteriophage Riley. The rest of the plates were fully lysed. Table 1 shows that
mutants 1041, 1043, and 1221 were resistant to bacteriophage Riley. The other mutants either
did not grow in culture well enough to plate or they were infected by Riley. The results of the
spot tests are illustrated in Figure 8 where there is only a clearing in D, as indicated by the red
circle, while A, B, and C did not have clearings. Mutants1041, 1043, and 1221 are resistant to
bacteriophage Riley since the phage could not make a clearing in their lawns. There were some
mutants, such as 1335, that did show some promise of being resistant. However the resistance
results were inconsistent between each spot test, so they were disregarded.
Table 1: Mutants Tested Against Bacteriophage Riley
Mutant

Resistant (Yes/No)

1034

No growth

1041

Yes

1043

Yes

1048

No

1221

Yes

1335

No

1336

Inconsistent
resistance between
spot tests

1339

No growth

A

B

C

D

Figure 8: Spot Tests: A) 1043 against Riley B)
1041 against Riley C) 1221 against Riley D)
1048 against Riley
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DISCUSSION AND CONCLUSIONS
From the data we obtained, we can conclude that transposon mutagenesis can be used
to create phage resistant mutants of Gram-positive bacteria. From these mutants, three were
found to be resistant to bacteriophage Riley. The BtK gene that encodes the receptor for Riley
can be said to have been interrupted by the transposon by these results.
Currently, there is a lack of information on Bacillus species surface receptors for phages.
Analyzing the genes that allow for phages to interact with BtK will allow researchers to find
specific phages that can be used for phage therapy. One reason why there is a lack of
information for Bacillus RBPs is that the bacteria are Gram-positive, thus making it harder to
complete mutagenesis and DNA extraction.
The Ez-Tn5 <R6kγori/Kan-2> transposon kit was chosen because it has been proven to
be effective for multiple different strains of gram-positive bacteria including Bacillus subtilis. A
problem that kept arising was that the yield of mutants was always small. The number of
mutants created should have been in the hundreds, but only a total of 134 mutants were
isolated on the KAN plates. We expected that the number of mutants needed to find a few that
were resistant to Riley would have to be in the hundreds. Instead, we were able to isolate three
that were consistently resistant. Having a large percentage of the mutants being resistant might
mean that there are multiple receptors for this phage instead of just one.
Once the information about the genes that control the interaction between phages and
the bacteria they infect has been found, it can be used to enhance phage therapy. Researchers
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may be able to genetically engineer phages that bind more tightly to the receptor to guarantee
high rate of infection. This can only be done if the researcher knows what protein controls the
interactions and what makes up its macromolecular structure. Researchers could also use this
information to genetically engineer other phages that are highly virulent so that they can infect
the same bacterial strain.
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FUTURE WORK
Future work will be to extract DNA from the mutant cells, ligate the DNA with the
transposon into a plasmid, and then complete plasmid transformation into E. coli. The
transformation step will allow for the plasmid to be separated from the mutant’s chromosomal
DNA. The DNA can then be extracted and purified from the E. coli cells to allow for it to be
sequenced. The sequenced DNA can then be compared to the BtK library to find which protein
was interrupted.
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